Headquartered in Saratoga, CA with subsidiaries in Bangalore, and Australia, Bugworks Research announced that the first human dose was administered in a phase 1 clinical trial. This trial to evaluate BWC0977, a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), was supported by Boston University’s CARB-X — Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator — a global nonprofit entity.
BWC0977 is a highly potent, intravenous broad-spectrum antibiotic with the potential for oral administration for the treatment of serious multi drug resistant (MDR) gram-negative infections such as acinetobacter baumannii, and drug resistant gram-positive infections such as methicillin resistant staphylococci (MRSA) to mention a few. It can address many serious hospital and community infections and combat a broad spectrum of pathogens that are biothreats. It has the potential of becoming a breakthrough antibiotic, not seen since the 1960s reports Pharmabiz.
Last updated: December 26th, 2025
